“我们将继续经历鼓励我们的MBD和COVID-19项目的进展，在瑞典被授予在MBD 2期试验，并授权在澳大利亚开始AT-H20万博体育怎么买足彩1的2期研究与相关呼吸道疾病的新监管机构的批准COVID-19,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer.
“与此同时，我们继续享受强大的资产负债表，我们在过去的三个季度中大大扩展，并将促进我们在近期的发展计划。As we actively explore the possibility for strategic expansion into other areas where we might see near-term milestones and results, we also urge all of our shareholders to exercise their right to vote at our special stockholder’s meeting on September 7, 2021. We urge a vote in favor of the proposal to increase authorized shares, which will provide the Company with the flexibility to issue shares as part of these potential acquisitions, collaborations and partnerships, a common strategy successful biotech companies seeking to grow shareholder value employ in order to create a more attractive opportunity for all. We look forward to continuing to update our stockholders on these opportunities as they develop,” concluded Dr. Quay.
研究和开发费用 R＆d开支止的三个月2021 6月30日，分别约为3,799,000 $，增长约$二百一十四万六千或总R＆d开支止的三个月约$ 1,653,000到2020年6月30日，130％。R＆d开支止六个月2021 6月30日，分别约为5177000 $，增长约$二百五十八万五千或100％的总R＆d开支止六个月约$ 2,592,000到2020年6月30日。在R＆d费用的增加主要归因于增加了约1309000 $临床试验费用，由于增加了两个员工增加的约为21.1 $补偿，相比于2020年同期也包括在R＆d费用是increase of $1,000,000 attributable to a one-time fee we paid in June 2021 to a U.S. leading research institution for the exclusive right to negotiate for the acquisition of the world-wide rights to two oncology R&D programs. We expect our R&D expenses to continue to increase into 2021 as we seek to commence a clinical study of AT-H201, complete studies of AT-301, launch a Phase 2 clinical trial of Endoxifen in women with high breast density, and continue the development of other indications and therapeutics.
在本新闻稿中的前瞻性陈述，奥斯卡没有义务更新，可能会受风险和不确定性，可能导致实际结果与预期或估计的未来结果有关，包括与中期之间的任何变化相关的风险和不确定性FDA的最终临床结果，行动和不间断，atossa所需的监管批准的结果或时间，包括开始研究at-H201，301和内胃癌，低于预期的患者入学率，估计的市场规模of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.